BACKGROUND: Glioblastoma multiforme (GBM) is a form of highly malignant brain tumour. Temozolomide (TMZ) is the standard agent for GBM, but TMZ-resistance is common and accounts for many treatment failures. MicroRNA-21 (miR-21) is a non-coding RNA that plays critical roles in many biological processes in cancer, including chemoresistance. We investigated miR-21 expression and the effect of miR-21 inhibition in GBM with acquired TMZ resistance. MATERIALS AND METHODS: Human GBM cell line D54MG was treated with TMZ chronically to develop a chemoresistant subclone. MiR-21 inhibition was achieved by transfection with anti-mir-21 oligonucleotide. RESULTS: Chronic TMZ exposure resulted in acquired TMZ-resistance and elevated miR-21 expression. Concomitant treatment with miR-21 inhibitor and TMZ resulted in a significantly higher apoptotic rate than TMZ treatment alone. CONCLUSION: MiR-21 may have a potential for use as a biomarker of acquired TMZ resistance. MiR-21 inhibition can be further explored as a potential chemotherapy adjunct in the treatment of TMZ-resistant GBM.
BACKGROUND:Glioblastoma multiforme (GBM) is a form of highly malignant brain tumour. Temozolomide (TMZ) is the standard agent for GBM, but TMZ-resistance is common and accounts for many treatment failures. MicroRNA-21 (miR-21) is a non-coding RNA that plays critical roles in many biological processes in cancer, including chemoresistance. We investigated miR-21 expression and the effect of miR-21 inhibition in GBM with acquired TMZ resistance. MATERIALS AND METHODS:Human GBM cell line D54MG was treated with TMZ chronically to develop a chemoresistant subclone. MiR-21 inhibition was achieved by transfection with anti-mir-21 oligonucleotide. RESULTS: Chronic TMZ exposure resulted in acquired TMZ-resistance and elevated miR-21 expression. Concomitant treatment with miR-21 inhibitor and TMZ resulted in a significantly higher apoptotic rate than TMZ treatment alone. CONCLUSION:MiR-21 may have a potential for use as a biomarker of acquired TMZ resistance. MiR-21 inhibition can be further explored as a potential chemotherapy adjunct in the treatment of TMZ-resistant GBM.
Authors: Young-Eun Seo; Hee-Won Suh; Raman Bahal; Alexander Josowitz; Junwei Zhang; Eric Song; Jiajia Cui; Seth Noorbakhsh; Christopher Jackson; Tom Bu; Alexandra Piotrowski-Daspit; Ranjit Bindra; W Mark Saltzman Journal: Biomaterials Date: 2019-02-14 Impact factor: 12.479
Authors: Laura Giunti; Martina da Ros; Serena Vinci; Stefania Gelmini; Anna Lisa Iorio; Anna Maria Buccoliero; Stefania Cardellicchio; Francesca Castiglione; Lorenzo Genitori; Maurizio de Martino; Sabrina Giglio; Maurizio Genuardi; Iacopo Sardi Journal: Am J Cancer Res Date: 2014-12-15 Impact factor: 6.166
Authors: Charbel Darido; Smitha R Georgy; Carleen Cullinane; Darren D Partridge; Rachael Walker; Seema Srivastava; Suraya Roslan; Marina R Carpinelli; Sebastian Dworkin; Richard B Pearson; Stephen M Jane Journal: Cell Death Differ Date: 2017-12-13 Impact factor: 15.828